Call for Abstract

5th International Pharmacy Conference, will be organized around the theme “Innovations in Exertions of Pharmacy”

Pharmacy 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharmacy 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Pharmacy is the science and technique of preparing and dispensing drugs. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of Pharmaceutical drug.

  • Track 1-1Hospital Pharmacy
  • Track 1-2Pharmacology
  • Track 1-3Medicinal Chemistry
  • Track 1-4Pharmacotherapy
  • Track 1-5Clinical Pharmacy
  • Track 1-6Pharmacist

Clinical trial is a research study conducted to investigate new treatments such as a new drug compound in human volunteers or research participants. Each clinical trial is designed to learn about a potential treatment and its effect on humans. Before a new treatment is tried in human, extensive laboratory testing are done to identify promising compounds and Toxicological (safety) tests conducted to determine possible risks. The treatment with the most promising results is then moved into clinical trials. The results of clinical trials can make a difference in the care of patients by providing information about the benefits and risks of new therapeutic, preventative, or diagnostic products or interventions. Clinical trials also can contribute invaluable information about the benefits and safety of existing Drug therapies, providing doctors and patients with reliable information for choosing between alternative treatments.

  • Track 2-1Cancer Clinical Trial
  • Track 2-2Screening Trails
  • Track 2-3Cancer Clinical Trial
  • Track 2-4Pilot Studies and feasbility studies
  • Track 2-5Research and Developments in Clinical trials

Good pharmacovigilance practice (GPvP)-minimum standard for monitoring the safety of medicines on sale to the public in the EU. It is a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU). GVP apply to marketing-authorisation holders, European Medicines Agency and medicines regulatory authorities in EU Member States. They cover medicines authorised centrally via the Agency as well as medicines authorised at national level.

  • Track 3-1Significance of Pharmacovigilance
  • Track 3-2Methods of Pharmacovigilance
  • Track 3-3Drug Saftey
  • Track 3-4Pharmacovigilance and Health care System

Pharmaceutical Analysis is an Analytical Method used to determination the quality and quantity of the pharmaceutical products. It also gives the information about the Purity and Safety of the products. Briefly it can be described as it identifies, determines, quantifies, purifies and separates the active compound from the mixture.

  • Track 4-1Chromatographic techniques
  • Track 4-2Special techniques
  • Track 4-3Quality control and Quality assurance
  • Track 4-4Validation methods
  • Track 4-5Quantitative and qualitative analysis in the drug screening process

Regulatory Affairs is a profession within regulated industries namely-pharmaceuticals, Medical devices, energy and banking. It has specific meaning within healthcare industries namely- pharmaceuticals, medical devices, biologics and functional foods. Regulatory Affairs in the pharma industry may be defined as "The interface between the pharmaceutical company and the regulatory agencies across the world." Regulatory agency in the present context may be defined as "The competent government agency which is responsible for ensuring that medicines work and are acceptably safe."

  • Track 5-1Regulatory Guidelines
  • Track 5-2Global Regulatory Strategy
  • Track 5-3Framework of Regulatory Affairs
  • Track 5-4Regulatory Affairs in Clinical Trails

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, clinical trials on humans, and may include the step of obtaining regulatory approval to market the drug.

  • Track 6-1Therapeutic drug monitoring
  • Track 6-2Drug interactions
  • Track 6-3Clinical Drug Development

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve scientific site-targeting within the body, or it might involve facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of drug presence. Drug delivery is often approached via a drug's chemical formulation, but it may also involve medical devices or drug-device combination products.

  • Track 7-1Strategies for Drug Delivery
  • Track 7-2Routes of Drug Administration
  • Track 7-3Major Challenges in Drug Delivery
  • Track 7-4Drug Delivery and Device Development
  • Track 7-5Recent Advances in Drug Delivery
  • Track 7-6Drug Delivery Equipments and Machinery

Good manufacturing practices (GMP) are the practices required in order to conform to the guidelines recommended by agencies that control authorization and licensing for manufacture and sale of food, drug products, and active pharmaceutical products. These guidelines provide minimum requirements that a pharmaceutical or a food product manufacturer must meet to assure that the products are of high quality and do not pose any risk to the consumer or public.

Good manufacturing practices, along with good agricultural practices, good laboratory practices and good clinical practices are overseen by regulatory agencies in the United States, Canada, Europe, China, and other countries.

  • Track 8-1Current Regulations And Quality Standards
  • Track 8-2Quality Control & Quality Assurance
  • Track 8-3GMP in Food Industry
  • Track 8-4Current GMP Guidelines & Validation

Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.

Birkett (2003) defined bioequivalence by stating that, "two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bio availabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards."

  • Track 9-1Bioequivalence Protocols : In vivo/ In vitro studies
  • Track 9-2Managing BA/BE Studies
  • Track 9-3Regulatory Requirements for BE
  • Track 9-4Advances in BABE
  • Track 9-5Biosimilars
  • Track 9-6BABE Study Designs

Pharmacology is the branch of medicine and biology concerned with the study of drug action,where a drug can be broadly defined as any man-made, natural, or endogenous (from within body) molecule which exerts a biochemical and/or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

Pharmacotherapy is therapy using pharmaceutical drugs, as distinguished from therapy using surgery (surgical therapy), radiation (radiation therapy), movement (physical therapy), or other modes. Among physicians, sometimes the term medical therapy refers specifically to pharmacotherapy as opposed to surgical or other therapy; for example, in oncology, medical oncology is thus distinguished from surgical oncology.

  • Track 10-1Neuropharmacology and Psychopharmacology
  • Track 10-2Ethnopharmacology
  • Track 10-3Advances in Pharmacological Research
  • Track 10-4Pharmacokinetics and Pharmacodynamics

A drug interaction is a situation in which a substance (usually another drug) affects the activity of a drug when both are administered together. This action can be synergistic (when the drug's effect is increased) or antagonistic (when the drug's effect is decreased) or a new effect can be produced that neither produces on its own. Typically, interactions between drugs come to mind (drug-drug interaction). However, interactions may also exist between drugs and foods (drug-food interactions), as well as drugs and medicinal plants or herbs (drug-plant interactions). People taking antidepressant drugs such as monoamine oxidase inhibitors should not take food containing tyramine as hypertensive crisis may occur (an example of a drug-food interaction). These interactions may occur out of accidental misuse or due to lack of knowledge about the active ingredients involved in the relevant substances.

Biomedical sciences, are a set of applied sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. Explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science.